Pancreatic Enzyme Replacement Therapy
The question
To ask the Secretary of State for Health and Social Care, what steps he is taking to address the shortages in Pancreatic enzyme replacement medication.
Answered by Karin Smyth
The Department is continuing to engage with all suppliers of pancreatic enzyme replacement therapy (PERT) to boost production to mitigate the supply issue. Increased volumes of PERT are expected for 2025, and specialist importers have sourced unlicensed stock to assist in covering the gap in the market. In December 2024, the Department issued further management advice to healthcare professionals. This includes actions for clinicians to consider unlicensed imports when licensed stock is unavailable and for integrated care boards to ensure local mitigation plans are put in place and implemented. The Department, in collaboration with NHS England, has created a public facing page to include the latest update on PERT availability and easily accessible prescribing advice.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →